Objective: Assessing a diverse biomarker panel (NT-proBNP, TNF-α, galectin-3, IL-6, Troponin I, ST2 and sFlt-1) to detect subclinical cardiotoxicity after treatment with anthracyclines. Methods: Of 55 breast cancer patients biomarkers were assessed and echocardiography was performed one year after treatment with anthracyclines. Results: 29.1% of patients showed abnormal biomarker levels: NT-proBNP in 18.2%, TNF-α and Galectin-3 in 7.3%. IL-6, troponin I, ST2 and sFlt-1 were normal in all patients. A correlation between left ventricular ejection fraction (LVEF) and NT-proBNP was observed (r = −0.564, p ≤ 0.01). Conclusion: The evaluated biomarkers do not contribute to early detection. Future research should focus on NT-proBNP.
Boxtel, W., Bulten, B., Mavinkurve-Groothuis, A. M., Bellersen, L., Mandigers, C. M., Joosten, L. A., ... van Laarhoven, H. W. (2015). New biomarkers for early detection of cardiotoxicity after treatment with docetaxel, doxorubicin and cyclophosphamide. Biomarkers, 20(2), 143-148. https://doi.org/10.3109/1354750X.2015.1040839